The role of bone marrow derived-mesenchymal stem cells in attenuation of kidney function in rats with diabetic nephropathy

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Aziz, Mohamed Talaat Abdel ^a   Wassef, Mohamed Abdel Aziz ^a   Ahmed, Hanan Hosni ^a   Rashed, Laila ^a   Mahfouz, Soheir ^b   Aly, Mayssa Ibrahim ^b   Hussein, Rania Elsayed ^a   Abdelaziz, Mai ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Diabetic nephropathy; Mesenchymal stem cells; Stem cells therapy

Indexed keywords

ALBUMIN; CREATININE; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UREA;

ALBUMIN URINE LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAX GENE; BCL2 GENE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; KIDNEY FUNCTION; LIMIT OF QUANTITATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PRIORITY JOURNAL; RAT; TGFB GENE; TNFA GENE; UREA BLOOD LEVEL; URINE LEVEL;

EID: 84928616879     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-34     Document Type: Article

References (49)

1. Sho-ichi Y, Takanori M: Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 2010, 3:101-108.
2. Forbes JM, Fukami K, Cooper ME: Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 2007, 115:69-84.
3. Schrijvers BF, De Vriese AS, Flyvbjerg A: From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004, 25:971-1010.
4. Navarro-Gonzalez JF, Mora-Fernandez C: The role of inflammatory cytokines in diabetic nephropathy. J AmSocNephrol 2008, 19:433-442.
5. Weissman IL, Stem cells: Units of development, units of regeneration, and units in evolution. Cell 2000, 100:157-168.
6. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH: Immunomodulation by mesenchymal stem cells: A potential therapeutic strategy for type 1 diabetes. Diabetes 2008, 57:1759-1767.
7. Volarevic V, Al-Qahtani A, Arsenijevic N, Pajovic S, Lukic ML: Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producingmesenchymal stem cells as modulators of diabetogenesis. Autoimmunity 2010, 43:255-263.
8. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W: A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009, 54:2277-2286.
9. Lee JS, Hong JM, Moon GJ, Ahn YH, Bang OY: A long-Term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010, 28:1099-1106.
10. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
11. Zhang M, Mal N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB, Koc ON, Penn MS: SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 2007, 21:3197-3207.
12. Togel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C: Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007, 292:F1626-35.
13. Zhou H, Tian H, Long Y, Zhang XX, Zhong L, Deng L, Chen XH, Li XQ: Mesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in rats. Chin Med J 2009, 122:2573-2579.
14. Abdel Aziz MT, Atta H, Mahfouz S, Yassin HM, Rashed LA, Sabry D, Abdel Wahab Z, Taha F, Abdel Aziz G, El Sayed AM, Sayed M: A study on the protective effect of bone marrow derived mesenchymal stem cells on chronic renal failure in rats. Stem cell studies 2011, 1:e11.
15. Abdel Aziz MT, Atta H, Mahfouz S, Fouad HH, Roshdy NK, Ahmed HH, Rashed LA, Sabry D, Hassouna AA, Hasan NM: Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver cirrhosis. Clin Biochem 2007, 40:893-899.
16. Flyvbjerg: Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000, 43:1205-1223.
17. Galkina E, Ley K: Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006, 17:368-377.
18. Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant 2004, 19:2987-2996.
19. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Tesch GH: Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 2005, 16:1711-1722.
20. Tansy MG, Szymkowski DE: The TNF superfamily in 2009: New pathways, new indications, and new drugs. Drug discovery Today 2009, 2009 (14):1082-1088.
21. Ortiz A, Bustos C, Alonso J, Alcazar R, Lopez-Armada MJ, Plaza JJ, González E, Egido J: Involvement of tumor necrosis factor-Alpha in the pathogenesis of experimental, and human glomerulonephritis. Adv Nephrol Necker Hosp 1995, 24:53-77.
22. Bertani T, Abbate M, Zoja C, Coma D, Perico N, Ghezzi P, Remuzzi G: Tumor necrosis factor induces glomerular damage in rabbit. Am J Pathol 1989, 134:419-430.
23. Laster SM, Wood JG, Gooding LR: Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 1988, 141:2629-2634.
24. Boyle JJ, Weissberg PL, Bennett MR: Tumor necrosis factor-Alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol 2003, 23:1553-1558.
25. Baud L, Perez J, Friedlander G, Ardaillou R: Tumor necrosis factor stimulates prostaglandin production and cyclic AMP levels in rat cultured mesangial cells. FEBS Lett 1998, 239:50-54.
26. Wojciak-Stothard B, Entwistle A, Garg R, Ridley AJ: Regulation of TNF-Alphainduced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. J Cell Physiol 1998, 176:150-165.
27. Raedke HH, Meier B, Topley N, Fluge J, Habermehl GG, Resch K: Interleukin 1-Alpha and tumor necrosis factor-Alpha induce oxygen radical production in mesangial cells. Kidney Int 1990, 37:767-775.
28. Sugimoto H, Shikata K, Wada J, Horiuchi S, Makino H: Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: Aminoguanidine ameliorates the overexpression of tumor necrosis factor-α and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 1999, 42:878-86.
29. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ: Receptorspecific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 1992, 89:2873-7.
30. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A, Migheli A, Stern D: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993, 143:1699-712.
31. Suzuki D, Toyoda M, Yamamoto N, Miyauchi M, Katoh M, Kimura M, Maruyama M, Honma M, Umezono T, Yagame M: Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy. Intern Med 2006, 45:435-41.
32. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A: Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988, 240:1546-8.
33. Rashid G, Benchetrit S, Fishman D, Bernheim J: Effect of advanced glycation end-products on gene expression and synthesis of TNF-α and endothelial nitric oxide synthase by endothelial cells. Kidney Int 2004, 66:1099-106.
34. Matem T, Melek Ö: The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy. Acthis 2011, 12:003.
35. Cornacchia F, Fornoni A, Plati AR, Thomas A, Wang Y, Inverardi L, Striker LJ, Striker GE: Glomerulosclerosis is transmitted by bone-marrow drivedmesangial progenitors. J Clin Invest 2001, 108:1649-1656.
36. Poulsom R, Forbes SJ, Hodivala-DHke K, Ryan E, Wyles S, Navaratnarasah S, Jeffery R, Hunt T, Alison M, Cook T, Pusey C, Wright NA: Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol 2001, 195:229-235.
37. Anglani F, Forino M, Del Prete D, Tosetto E, Torregrossa R, D'Angelo A: In search of adult renal stem cells. J Cell Mol Med 2004, 8:474-487.
38. Morigi M, Introna M, Imberti B, Corna D, Abbate M, Rota C, Rottoli D, Benigni A, Perico N, Zoja C, Rambaldi A, Remuzzi A, Remuzzi G: Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 2008, 26:2075-2082.
39. Ling L, Truong P, Igarashi P, Lin F: Renal and bone marrow cells fuse after renal ischemic injury. J Am Soc Nephrol 2007, 18:3067-3077.
40. Rookmaaker MB, Verhaar MC, de Boer HC, Goldschmeding R, Joles JA, Koomans HA, Gröne HJ, Rabelink TJ: Met-RANTES reduces endothelial progenitor cell homing to activated (glomerular) endothelium in vitro and in vivo. Am J Physiol Renal Physiol 2007, 293:F624-630.
41. Ito T, Suzuki A, Okabe M, Imai E, Hori M: Application of bone marrow-derived stem cells in experimental nephrology. Exp Nephrol 2001, 9:444-450.
42. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C: Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005, 289:F31-42.
43. Duffield JS, Bonventre JV: Kidney tubular epithelium is restored withoutreplacement with bone marrow-derived cells during repair after ischemic injury. Kidney Int 2005, 68:1956-1961.
44. Chishti AS, Sorof JM, Brewer ED, Kale AS: Long-Term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am J Kidney Dis 2001, 38:754-760.
45. Shimizu A, Masuda Y, Mori T, Kitamura H, Ishizaki M, Sugisaki Y, Fukuda Y: Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 2004, 15:2655-2665.
46. Abdel Aziz MT, Wassef MA, Rashed LA, Mhfouz S, Omar N, Elsebaie MM: Mesenchymal stem cells therapy in acute renal failure: possible role of hepatocyte growth factor. J Stem Cell Res Ther 2011, 1:3.
47. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S, Star RA: Interleukin-10 inhibitsischemic and cisplatin-induced acute renal injury. Kidney Int 2001, 60:2118-2128.
48. Semedo P, Palasio CG, Oliveira CD, Feitoza CQ, Gonçalves GM, Cenedeze MA, Wang PM, Teixeira VP, Reis MA, Pacheco-Silva A, Câmara NO: Early modulation of inflammation by mesenchymal stem cell after acute kidney injury. Int Immunopharmacol 2009, 9:677-682.
49. Zhang Y, Ye C, Wang G, Gao Y, Tan K, Zhuo Z, Liu Z, Xia H, Yang D, Li P: Kidney-Targeted transplantation of mesenchymal stem cells by ultrasound-Targeted microbubble destruction promotes kidney repair in diabetic nephropathy rats. Biomed Res Int 2013, 2013:526367.